News and Announcements
PwC Bioforum April 2014
- Published April 23, 2014 2:53PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Time for action: Policy and the Life Sciences sector
With the first budget of Australia’s new Federal Government rapidly approaching it seems a good time to reflect on how current policies are affecting technology rich, high risk and high reward areas of the economy like Life Sciences companies.
There have always been differing views on the role of Government in supporting industry and the extent to which free market forces should be allowed to dictate outcomes. This debate is particularly important to the Life Sciences sector.
Life Sciences companies are unique in many ways. To start, they operate in a constantly changing technological, scientific and regulatory environment, they require substantial amounts of capital very early on in their lifecycle and they are inherently risky for investors. When you add to this mix the sector’s public importance in driving enhancements in the quality and longevity of life there are difficult decisions to be made as to the role Governments should play in supporting
the sector.
For more information or to download the BioForum please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
